Putting the award page together from the records…
Putting the award page together from the records…
Vitrivax, Inc. received this contract from Defense Threat Reduction Agency, Defense Threat Reduction Agency: $14.51M obligated so far for national defense r&d services; defense-related activities; experimental development. It runs to 2027-02-11, or to 2028-01-11 if every option is exercised.
Key facts · data as of Oct 23, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award HDTRA123C0009, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_HDTRA123C0009_9700_-NONE-_-NONE-
Vitrivax, Inc.: all federal awards · Department of Defense: spending · Defense Threat Reduction Agency: what it buys · The follow-on: recompete brief
OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS
Up for re-bid: ends 2027-02-11. Recompete brief → · Research and Development Innovations Broad Agency Announcement ↗
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
2 subawards totaling $815.0K (5.6% of what was obligated), as Vitrivax, Inc. reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| University of Nevada | $565.1K | 1 | NV | 2023-03-22 | 2023-03-22 |
| Sia Partners U.S., Inc. | $250.0K | 1 | MD | 2023-03-30 | 2023-03-30 |
| Date | To | Amount | For |
|---|---|---|---|
| 2023-03-22 | University of Nevada | $565.1K | PROVIDE DRUG SUBSTANCE FOR USE IN PLATFORM TECHNOLOGY |
| 2023-03-30 | Sia Partners U.S., Inc. | $250.0K | CONTRACT COMPLIANCE AND PROGRAM MANAGEMENT SUPPORT |
14 actions since 2023-01-10. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-05-14 | P00012 | Supplemental agreement (work within scope) | $1.41M | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2026-01-20 | P00011 | Option exercised | $4.00M | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2025-07-30 | P00010 | Supplemental agreement (work within scope) | $0 | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2025-06-02 | ARZ998 | Vendor address changed | $0 | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2025-05-01 | P00009 | Administrative change | $0 | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2025-01-22 | P00008 | Option exercised | $3.24M | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2024-12-19 | P00007 | Administrative change | $0 | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2024-06-06 | P00006 | Administrative change | $0 | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2024-04-18 | P00005 | Funding only | $2.25M | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2024-01-18 | P00004 | Administrative change | $0 | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2024-01-04 | P00003 | Option exercised | $822.8K | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2023-11-03 | P00002 | Supplemental agreement (work within scope) | $1.39M | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2023-02-09 | P00001 | Funding only | $737.5K | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
| 2023-01-10 | 0 | $656.1K | OPTIMIZATION AND PRODUCTION OF SINGLE-SHOT VACCINES FOR MELIOIDOSIS AND GLANDERS |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗